All News

Chronic prostatitis/chronic pelvic pain syndrome is a complex, heterogeneous syndrome in terms of etiology and symptoms, making its treatment difficult. Thus, a first step to improved management of these conditions is to better classify and stratify patients.

A single injection of a bacterial protoxin can reduce lower urinary tract symptoms secondary to BPH and improve quality of life.

In the Internet Age, it's all about making sure that Google ranks you on page one in position one.

Hopefully, "hormonal downsizing" (UT, April 2010, pg. 4) is the only reason that any patient would receive ADT prior to RT for low-risk disease.

When it comes to etiology and treatment of chronic pelvic pain, one size doesn't fit all.

There's lot to think about when it comes to adopting an electronic health record system.

Men with moderate to severe lower urinary tract symptoms who were treated with botulinum toxin A injection found their symptoms markedly improved.

In the minority of patients who experience postoperative urinary incontinence following photoselective vaporization of the prostate for BPH, the more severe symptoms are associated with age and preoperative prostate size.

Percutaneous nephrolithotomy is considered the gold standard for the removal of large renal stones. Until recently, however, the procedure's efficacy had not been verified by a clinical study as large as a gold-standard procedure would seem to require.

Conflicting data on fascial defect size and port fixity render any perception of surgical advantage per port type as theoretical. Thus, regarding this aspect, the decision to use bladed or non-bladed trocars is likely best left to surgeon preference.

The introduction of the computer into the doctor-patient interaction has both benefits and risks.

New urology products and services from American Medical Systems, Caris Life Sciences, UROSKOP Omnia, and Covidien.

Research into the effects of gastric bypass surgery on sperm quality shows no improvement in reproductive capacity among men who undergo the procedure.

This list of U.S.-based National Institutes of Health trials is derived from the NIH's database and includes U.S. phase I and II localized prostate cancer trials that are currently recruiting participants. This list is current as of April 28, 2010.

Targets for improving the state of management of advanced prostate cancer include the development of new diagnostic modalities with better performance in detecting recurrent disease, additional monotherapy or combination treatment options, and strategies for mitigating the risks of androgen deprivation therapy.

Studies on minimally invasive surgery will again have a prominent place among research being presented on localized prostate cancer at the AUA annual meeting.

Don't give up on instillation for interstitial cystitis when lidocaine doesn't help. Bupivacaine can come to the rescue.

The mechanism of action is somewhat unclear for newer procedures to correct male stress urinary incontinence such as slings, but a new cadaveric model appears to offer valuable insight.

A lower lithotomy position is an acceptable standard approach when performed with adjustable stirrups and pneumatic compression stockings.

A post hoc analysis of two phase III antimuscarinic trials shows that multiple medication use is a major factor in failure of antimuscarinics.

Newer treatments for male sexual dysfunction highlighted at the 2010 AUA annual meeting are allowing urologists to improve patients' quality of life and satisfaction with treatment.

The artificial urinary sphincter appears to be efficacious for the treatment of male stress urinary incontinence, even in complex patients with histories of radiation therapy or urethral surgery.

Pediatric urology is moving fast, bringing developments that will also change not just adult urology, but the practice of medicine as well.

Over the past 2 decades, the field of urology has made dramatic progress in understanding the etiology and pathophysiology of BPH/lower urinary tract symptoms.

Urology drugs and devices that are in the pipeline from Rexahn Pharmaceuticals, Inc., CytRx Corp., Urigen Pharmaceuticals, Inc., Seattle Genetics, Inc., Agensys, Inc., and Millennium: The Takeda Oncology Co.

In diagnosing and treating infection and inflammation, urologists increasingly are using approaches tailored to specific pathogens, patients, and clinical situations.

This year's AUA annual meeting will bring an important first for interstitial cystitis: AUA will be issuing guidelines for diagnosis and treatment.